Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844647 | 1.00 | HTR2A (0.47) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| SCHEMBL29844508 | 0.91 | CDK5 (0.37) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| SCHEMBL29844446 | 0.91 | CDK5 (0.37) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| SCHEMBL275596 | 0.91 | CDK5 (0.37) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| Hydrochloric Acid SCHEMBL27734241 | 0.89 | CDK5 (0.36) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| Hydrochloric Acid SCHEMBL1114916 | 0.89 | CDK5 (0.36) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| SCHEMBL28342668 | 0.86 | TDO2 (0.48) | HTR2AHRH3CDK5CDK5R1NPC1 | |
| SCHEMBL18385998 | 0.83 | HTR2A (0.50) | HTR2AHRH3TSHRKMT2APOLB | |
| SCHEMBL261028 | 0.82 | HTR2A (0.58) | HTR2AHRH3TSHRKMT2APOLB | |
| SCHEMBL29639019 | 0.82 | HTR2A (0.58) | HTR2AHRH3TSHRKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714070-B1 | LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS | OPKO BIOLOGICS LTD (IL) | 2024-03-20 | — | — | EP | disclosed |
| EP-3302571-B1 | PEGYLATED OXYNTOMODULIN VARIANTS | OPKO BIOLOGICS LTD (IL) | 2020-11-18 | — | — | EP | disclosed |
| US-20200254065-A1 | LONG-ACTING GLP-2 ANALOGS | OPKO BIOLOGICS LTD. (IL) | 2020-08-13 | — | — | US | disclosed |
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-20180050113-A1 | PEGYLATED OXM VARIANTS | OPKO BIOLOGICS LTD. (IL) | 2018-02-22 | — | — | US | disclosed |
| US-20180050113-A1 | PEGYLATED OXM VARIANTS | OPKO BIOLOGICS LTD. (IL) | 2018-02-22 | — | — | US | disclosed |
| WO-2017212494-A1 | LONG-ACTING OXYNTOMODULIN FORMULATION AND METHODS OF PRODUCING AND ADMINISTERING SAME | OPKO BIOLOGICS LTD. (IL) | 2017-12-14 | — | — | WO | disclosed |
| US-9821070-B2 | Pegylated OXM variants | OPKO BIOLOGICS LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2009000523-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000523-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
| WO-2006097694-A2 | PEPTIDE SYNTHESIS SUPPORTED BY A SOLUBLE POLYMER | ACTIVOTEC SPP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
| EP-1620118-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004089280-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | PTMS, FIBP, FLT3 | HTR2A 1734/4885HRH3 2961/4885CDK5 1678/4885 |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | HGFAC, PTMS, PRMT9 | HTR2A 2114/4885HRH3 3102/4885CDK5 2264/4885 |
| US-20200254065-A1 | LONG-ACTING GLP-2 ANALOGS | GLP1R, GIPR, GCGR | HTR2A 342/4885HRH3 1060/4885CDK5 3463/4885 |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | VIP, PTMS, SSTR4 | HTR2A 4712/4885HRH3 3308/4885CDK5 2502/4885 |
| US-20180050113-A1 | PEGYLATED OXM VARIANTS | OXTR, OGFR, OGFRL1 | HTR2A 2021/4885HRH3 3702/4885CDK5 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.